Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Drug Overdose

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43871   clinical trials with a EudraCT protocol, of which   7290   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    13 result(s) found for: Drug Overdose. Displaying page 1 of 1.
    EudraCT Number: 2017-000246-21 Sponsor Protocol Number: PP100-001 Start Date*: 2017-04-25
    Sponsor Name:PledPharma AB
    Full Title: A Randomised Open Label Exploratory, Safety and Tolerability Study with PP100-01 in Patients Treated with the 12-hour Regimen of N-Acetylcysteine for Paracetamol/Acetaminophen Overdose
    Medical condition: The objective of this study is to develop a therapeutic regimen for paracetamol/acetaminophen overdose (POD) where a novel NAC 12hr regime is combined with a superoxide dismutase (SOD) mimetic, PP1...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10022117 - Injury, poisoning and procedural complications 10033295 Overdose PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-017800-10 Sponsor Protocol Number: CZB/4/722 Start Date*: 2010-04-01
    Sponsor Name:NHS Lothian [...]
    1. NHS Lothian
    2. University of Edinburgh
    Full Title: Scottish and Newcastle Anti-emetic Pre-treatment for Paracetamol Poisoning study (SNAP)
    Medical condition: Paracetamol overdose
    Disease: Version SOC Term Classification Code Term Level
    2.2 10033295 Overdose LLT
    2.2 10033297 accidental overdose LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-001877-34 Sponsor Protocol Number: HOT-Treated Start Date*: 2016-11-25
    Sponsor Name:South London and Maudsley NHS Foundation Trust [...]
    1. South London and Maudsley NHS Foundation Trust
    2. King's College London
    Full Title: Improving understanding of Heroin Overdose Testing: diamorphine dose-escalation testing in a treated population
    Medical condition: Opioid Overdose
    Disease: Version SOC Term Classification Code Term Level
    21.1 10022117 - Injury, poisoning and procedural complications 10033295 Overdose PT
    20.0 10022117 - Injury, poisoning and procedural complications 10033299 Overdose effect LLT
    20.1 10022117 - Injury, poisoning and procedural complications 10067695 Acute overdose LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-004072-22 Sponsor Protocol Number: NINA-1 Start Date*: 2017-12-07
    Sponsor Name:Norwegian University of Science and Technology (NTNU)
    Full Title: NTNU Intranasal Naloxone Trial Double blinded, double dummy, randomised controlled trial of intranasal naloxone for pre hospital use
    Medical condition: We investigate the reversal of opioid overdoses in the pre hospital setting
    Disease: Version SOC Term Classification Code Term Level
    20.0 10022117 - Injury, poisoning and procedural complications 10022117 Injury, poisoning and procedural complications SOC
    20.0 10022117 - Injury, poisoning and procedural complications 10071947 Exposures, chemical injuries and poisoning HLGT
    20.0 10022117 - Injury, poisoning and procedural complications 10035777 Poisoning and toxicity HLT
    21.1 10022117 - Injury, poisoning and procedural complications 10070863 Toxicity to various agents PT
    20.1 10022117 - Injury, poisoning and procedural complications 10072946 Opioid toxicity LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: View results
    EudraCT Number: 2009-015647-16 Sponsor Protocol Number: ANV-09-008 Start Date*: 2010-01-28
    Sponsor Name:GUIDE Clinic, St James's Hospital
    Full Title: The pharmacokinetics of once daily Kaletra and methadone in a population of HIV positiive drug users.
    Medical condition: HIV-1 Positive Injection Drug Users
    Disease: Version SOC Term Classification Code Term Level
    12.0 10020180 HIV positive LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-002073-26 Sponsor Protocol Number: 1125-ECIR Start Date*: Information not available in EudraCT
    Sponsor Name:Medical Center - University of Freiburg
    Full Title: Phase 1/2 Trial to determine the safety and efficacy of Extracorporeal photopheresis as treatment for steroid-refractory immune related adverse events after immune checkpoint inhibitor therapy
    Medical condition: Immune related adverse events induced by treatment with immune checkpoint inhibitors (monoclocanl antibodies against PD-1, PD-L1 or CTLA-4)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10022117 - Injury, poisoning and procedural complications 10043408 Therapeutic agent toxicity LLT
    26.1 10018065 - General disorders and administration site conditions 10067033 Drug side effect LLT
    24.0 10018065 - General disorders and administration site conditions 10061623 Adverse drug reaction PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-000305-24 Sponsor Protocol Number: AN01AC11 Start Date*: 2021-03-18
    Sponsor Name:Anebulo pharmaceuticals, Inc.
    Full Title: A randomized, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single oral doses of CB1 antagonist ANEB-001 in healthy occasional ...
    Medical condition: THC intoxication
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-002544-40 Sponsor Protocol Number: 5866 Start Date*: 2014-10-29
    Sponsor Name:Hôpitaux Universitaires de Strasbourg
    Full Title: THE TREATMENT OF HYPERTENSION ASSOCIATED WITH SEVERE PREECLAMPSIA. A RANDOMIZED CONTROLLED TRIAL OF URAPIDIL VERSUS NICARDIPINE. The URANIC trial.
    Medical condition: Hypertension associated with severe pre eclampsia
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-005192-89 Sponsor Protocol Number: C1231001 Start Date*: 2015-04-21
    Sponsor Name:Hospira UK Ltd.
    Full Title: Post-Marketing Observational Cohort Study of Patients with Inflammatory Bowel Disease (IBD) Treated with CT-P13 in Usual Clinical Practice (CONNECT-IBD)
    Medical condition: Inflamatory Bowel Disease (IBD)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10021973 Inflammatory bowel disease NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2017-000641-44 Sponsor Protocol Number: TailorDose-II Start Date*: 2017-04-28
    Sponsor Name:Karolinska intitutet
    Full Title: TailorDose®-II: Therapeutic dose monitoring of commonly used cytostatic drugs/regimes indicated for breast cancer
    Medical condition: Newly diagnosed pre- or post-operative breast cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006188 Breast cancer female NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-000439-14 Sponsor Protocol Number: CMBG453C12201 Start Date*: 2021-03-17
    Sponsor Name:Novartis Pharma AG
    Full Title: A phase II multi-center, single arm, safety and efficacy study of MBG453 in combination with azacitidine and venetoclax for the treatment of Acute Myeloid Leukemia (AML) in adult patients unfit for...
    Medical condition: Acute Myeloid Leukemia (AML) in adult patients unfit for chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-001997-70 Sponsor Protocol Number: EXCELLENCE/0421/0543v1 Start Date*: 2022-11-16
    Sponsor Name:University of Cyprus
    Full Title: Efficacy of Ketamine for the Prevention of Relapse in Patients with Opioid-Use Disorders (OUD)
    Medical condition: Methadone and buprenorphine comprise a first-line, evidence-based opioid substitution treatment (OST) for OUD patients. Unfortunately, retention and adherence to OST treatment is currently a major ...
    Disease: Version SOC Term Classification Code Term Level
    20.1 10037175 - Psychiatric disorders 10019935 Heroin addiction LLT
    20.1 10037175 - Psychiatric disorders 10030900 Opium addiction LLT
    20.0 10037175 - Psychiatric disorders 10012378 Depression PT
    21.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CY (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-002869-18 Sponsor Protocol Number: Start Date*: 2019-09-04
    Sponsor Name:Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust
    Full Title: A randomised, double-blind, placebo controlled trial of pramipexole in addition to mood stabilisers for patients with treatment resistant bipolar depression.
    Medical condition: Bipolar disorder (BD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10012386 Depression mental LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 03 19:19:52 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA